Tag: TVT 2022
Steps needed to include disadvantaged patients in mitral and tricuspid trials
Incentives for the enrolment of patients from socieconomically disadvantaged groups, as well as ...
TVT 2022: DAPT after Watchman FLX LAAO is comparable to currently approved regimens
Dual antiplatelet therapy (DAPT) after left atrial appendage occlusion (LAAO) using the Watchman...
TVT 2022: Late-breaking data point to favourable haemodynamic performance of latest-generation TAVI device
Transcatheter aortic valve implantation (TAVI) with the Acurate neo2 (Boston Scientific) device ...
TVT 2022: EXPAND registry shows benefit of MitraClip in patients outside of COAPT trial criteria
Analysis of the EXPAND registry, looking at one-year outcomes of MitraClip treatment in secondar...
TVT 2022: New data “debunk idea that patients with pacemakers may not be eligible for TEER”
Data from the first report on patients with a pacemaker lead across the tricuspid valve have sho...
